GRPH - Graphite Bio, Inc.
| Previous Close | 2.6500 |
| Open | 2.6512 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1000 |
| Day's Range | 2.6512 - 2.7350 |
| 52 Week Range | 1.5900 - 4.4800 |
| Volume | |
| Avg. Volume | 152,183 |
| Market Cap | 155.135M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.60 |
Simply Wall St.Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%
Key Insights Significant control over Graphite Bio by private equity firms implies that the general public has more...
ZacksShould You Buy Graphite Bio (GRPH) Ahead of Earnings?
Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Simply Wall St.
We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Business WireGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., March 20, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results.
Business WireGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
SOUTH SAN FRANCISCO, Calif., February 22, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to initiate a process to explore a range of strategic alternatives.
ZacksDown -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Reuters
Graphite Bio pauses early-stage blood disease therapy trial
Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious adverse event in the first patient dosed, sending its shares down nearly 48% in after hours trading. After being given Graphite's therapy, nula-cel, the patient showed prolonged low blood cell counts and required continued transfusion of blood, which the company believes is likely related to its treatment. Graphite said it has reported the incident to the U.S. Food and Drug Administration (FDA), and the patient has shown no evidence of blood cancer.
Business WireGraphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., January 05, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.
Business WireGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., December 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel (nula-cel), an investigational gene-edited
Business WireGraphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., November 21, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.
Business WireGraphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., November 09, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and third quarter 2022 financial results.
Business WireGraphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., November 03, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that two abstracts have been accepted as part of the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 10-13 in New Orleans and broadcast virtually from the E
- Simply Wall St.
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Business WireGraphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
SOUTH SAN FRANCISCO, Calif., October 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of its leadership team will participate in the 50th Annual Sickle Cell Disease Association of America (SCDAA) National Convention, taking place virtually October 11-15. The Convention is being held
Business WireGraphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., September 06, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 12:55 pm ET.
Business WireGraphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.
Business WireGraphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene e
Business WireGraphite Bio Announces Participation in Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 01, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.